Last reviewed · How we verify
NCT06357338
Differential Expression and Potential Value of c-MYC in Non-Invasive and Invasive Mammary Carcinoma
trial testing no intervention in Invasive Breast Cancer in 70 participants. Enrolling by invitation.
1 April 2025
Quick facts
| Lead sponsor | Marwa Mahmoud Hassan |
|---|---|
| Status | ENROLLING BY INVITATION |
| Study type | OBSERVATIONAL |
| Enrollment | 70 |
| Start date | 19 March 2024 |
| Primary completion | 1 April 2025 |
| Estimated completion | 1 April 2026 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- no intervention
Conditions studied
- Invasive Breast Cancer — all drugs for Invasive Breast Cancer →
Sponsor
Marwa Mahmoud Hassan
Who can join
15 and older, female only, with Invasive Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Retrospective observational study to evaluate c-MYC expression in non invasive and invasive mammry carcinoma
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06357338
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of no intervention
Trials testing the same drug.
- NCT07480057 — Assessment of Changes in Bone Mineral Metabolism After Liver Transplantation by Bone Mineral Densitometry · recruiting
- NCT07253506 — Turkish Adaptation, Validity, and Reliability Study of the Patient Experience With Treatment and Self-Management Scale i · not yet recruiting
- NCT07253519 — The Relationship Between Mood and Insomnia Severity and Caregiver Burden in Caregivers of Stroke · not yet recruiting
- NCT07194096 — Stress Hyperglycemia Ratio and Postoperative Delirium · not yet recruiting
- NCT07240337 — Botulinum Toxin Applications in Hemiplegic Patients · recruiting
Other recruiting trials for Invasive Breast Cancer
Currently open trials in the same condition.
- NCT07421479 — Patient-Derived Breast Cancer Organoids for Therapeutic Extracellular Vesicle Isolation (PDO-Mercurial01) · active not recruiting
- NCT06677944 — Preoperative Partial Breast Irradiation in Early-Stage Breast Cancer · Phase 2 · recruiting
- NCT05795101 — TRUDI: TDXD+Durva in HER2+/Low IBC · Phase 2 · recruiting
- NCT05383196 — Onvansertib + Paclitaxel In TNBC · Phase 1, PHASE2 · active not recruiting
- NCT05412225 — A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06357338 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Marwa Mahmoud Hassan
- Last refreshed: 10 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06357338.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing